Skip to main content
Erschienen in: Annals of Nuclear Medicine 10/2009

01.12.2009 | Review Article

Bibliometric study of radiation application on microdose useful for new drug development

verfasst von: Fumio Komoda, Akiko Suzuki, Kazuaki Yanagisawa, Tomio Inoue

Erschienen in: Annals of Nuclear Medicine | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

In spite of the sharp increase in both private and government R&D fund, the number of newly approved medicines for market had decreased since the 1990s. This is attributed to a large extent to the bottleneck in the critical path arising from the great disparity between animal model in pre-clinical trial and human model in clinical trial. This bottleneck may be expected to be gotten rid of by change in paradigm of drug development based on microdosing, which is enabled by radiation-related imaging technology. However, this is impossible without being accompanied by interdisciplinary joint researches, in which clinical investigators belonging to medical schools or hospitals play the most decisive role. In this article, authors verify based on bibliometrics that Japan has not employed the opportunity for revitalizing drug research activities because Japanese researchers’ attitude toward radiation technology may not be so positive in comparison with the US, and because the role which clinical investigators play in the phase of pre-clinical trial is smaller in Japan than in the US.
Literatur
1.
Zurück zum Zitat Jamison DT, Lau LJ, Wang J. Health’s contribution to economic growth in an environment of partially endogenous technical progress. NIH Working Paper. 2003;10. Jamison DT, Lau LJ, Wang J. Health’s contribution to economic growth in an environment of partially endogenous technical progress. NIH Working Paper. 2003;10.
2.
Zurück zum Zitat Thamlikitkul V. Bridging the gap between knowledge and action for health: case studies. Bul World Health Organ. 2006;84:603–7.CrossRef Thamlikitkul V. Bridging the gap between knowledge and action for health: case studies. Bul World Health Organ. 2006;84:603–7.CrossRef
3.
Zurück zum Zitat Smith A. Screening for drug discovery: the leading question. Nature. 2002;418:453–7.PubMed Smith A. Screening for drug discovery: the leading question. Nature. 2002;418:453–7.PubMed
4.
Zurück zum Zitat Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery. EMBO Rep. 2004;5:837–42.CrossRefPubMed Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery. EMBO Rep. 2004;5:837–42.CrossRefPubMed
7.
Zurück zum Zitat DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.CrossRefPubMed DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.CrossRefPubMed
8.
Zurück zum Zitat DeLamarter J. Biotechnology partnerships: medicine for an ailing industry? Nat Biotechnol. 2003;21:847–8.CrossRefPubMed DeLamarter J. Biotechnology partnerships: medicine for an ailing industry? Nat Biotechnol. 2003;21:847–8.CrossRefPubMed
9.
Zurück zum Zitat US Congressional Budget Office. Research and development in the pharmaceutical industry, a CBO study. Washington, DC: Congressional Budget Office; 2007. US Congressional Budget Office. Research and development in the pharmaceutical industry, a CBO study. Washington, DC: Congressional Budget Office; 2007.
10.
Zurück zum Zitat Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858:118–28.CrossRefPubMed Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858:118–28.CrossRefPubMed
12.
Zurück zum Zitat Japan Patent Office, Patent application and technology trends report 2007. Tokyo: Japan Institute of Invention and Innovation; 2008. Japan Patent Office, Patent application and technology trends report 2007. Tokyo: Japan Institute of Invention and Innovation; 2008.
14.
Zurück zum Zitat Ijichi H, Odagiri H. A comparative study of the Japanese pharmaceutical industry with the national innovation survey data. In: National Institute of Science and Technology Policy Discussion paper (43). National Institute of Science and Technology Policy 2006. http://www.nistep.go.jp/achiev/results01.html. Accessed 5 Aug 2008. Ijichi H, Odagiri H. A comparative study of the Japanese pharmaceutical industry with the national innovation survey data. In: National Institute of Science and Technology Policy Discussion paper (43). National Institute of Science and Technology Policy 2006. http://​www.​nistep.​go.​jp/​achiev/​results01.​html. Accessed 5 Aug 2008.
16.
Zurück zum Zitat Ministry of internal affairs and communications, Statistical Bureau. Report on the survey of research and development: 2005. Tokyo: Statistical Bureau; 2006. Ministry of internal affairs and communications, Statistical Bureau. Report on the survey of research and development: 2005. Tokyo: Statistical Bureau; 2006.
17.
Zurück zum Zitat Zerhouni EA. Translational and clinical science: time for a new vision. N Engl J Med. 2005;353:1621–3.CrossRefPubMed Zerhouni EA. Translational and clinical science: time for a new vision. N Engl J Med. 2005;353:1621–3.CrossRefPubMed
18.
Zurück zum Zitat Inoue T, Hayakawa K, Shiotari H, Takeda E, Torikoshi M, Nagasawa K, et al. Economic scale of utilization of radiation (III): medicine comparison between Japan and the USA. J Nucl Sci Technol. 2002;39:1114–9.CrossRef Inoue T, Hayakawa K, Shiotari H, Takeda E, Torikoshi M, Nagasawa K, et al. Economic scale of utilization of radiation (III): medicine comparison between Japan and the USA. J Nucl Sci Technol. 2002;39:1114–9.CrossRef
19.
Zurück zum Zitat Hayakawa K, Inoue T, Yanagisawa K, Shiotari H, Takeda E, Torikoshi M, et al. Economic scale of utilization of radiation in Japan: medical field. JAERI Conf. 2002;2002:193–206. Hayakawa K, Inoue T, Yanagisawa K, Shiotari H, Takeda E, Torikoshi M, et al. Economic scale of utilization of radiation in Japan: medical field. JAERI Conf. 2002;2002:193–206.
20.
Zurück zum Zitat Espada A, Molina-Martin M, Dage J, Kuo MS. Application of LC/MS and related techniques to high-throughput drug discovery. Drug Discov Today. 2008;13:417–23.CrossRefPubMed Espada A, Molina-Martin M, Dage J, Kuo MS. Application of LC/MS and related techniques to high-throughput drug discovery. Drug Discov Today. 2008;13:417–23.CrossRefPubMed
21.
Zurück zum Zitat Weber WA, Czernin J, Phelps ME, Herschman HR. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol. 2008;5:44–54.CrossRefPubMed Weber WA, Czernin J, Phelps ME, Herschman HR. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol. 2008;5:44–54.CrossRefPubMed
23.
Zurück zum Zitat Sugiyama Y. Basis for the conduct of microdosing clinical trials in Japan, third report draft guidance for exploratory investigational new drug clinical trials. Clin Eval. 2007;34:571–94. Sugiyama Y. Basis for the conduct of microdosing clinical trials in Japan, third report draft guidance for exploratory investigational new drug clinical trials. Clin Eval. 2007;34:571–94.
24.
Zurück zum Zitat Mayahara H. Safety of microdose clinical trials. Clin Eval. 2006;33:679–94. Mayahara H. Safety of microdose clinical trials. Clin Eval. 2006;33:679–94.
25.
Zurück zum Zitat Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol. 2004;58:601–8.CrossRefPubMed Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol. 2004;58:601–8.CrossRefPubMed
26.
Zurück zum Zitat Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in radiation to phase 0 trials. Br J Cancer. 2007;97:577–81.CrossRefPubMed Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in radiation to phase 0 trials. Br J Cancer. 2007;97:577–81.CrossRefPubMed
27.
29.
Zurück zum Zitat Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:1474–6.CrossRef Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:1474–6.CrossRef
30.
Zurück zum Zitat Hrusovsky K. By establishing a common thread in the test tube and the animal, scientists can greatly increase their confidence that the results of both experiments are clinically meaningful. Drug Discov Today. 2006;11:773–4.CrossRefPubMed Hrusovsky K. By establishing a common thread in the test tube and the animal, scientists can greatly increase their confidence that the results of both experiments are clinically meaningful. Drug Discov Today. 2006;11:773–4.CrossRefPubMed
31.
Zurück zum Zitat Hippel E. Democratizing innovation. Cambridge: The MIT Press; 2005. Hippel E. Democratizing innovation. Cambridge: The MIT Press; 2005.
32.
Zurück zum Zitat Mehta S. The emerging role of academia in commercializing innovation. Nat Biotechnol. 2004;22:22–4.CrossRef Mehta S. The emerging role of academia in commercializing innovation. Nat Biotechnol. 2004;22:22–4.CrossRef
34.
Zurück zum Zitat Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, et al. Early microdose drug studies in human volunteers can minimise animal testing, proceedings of a workshop organised by volunteers in research and testing. Eur J Pharm Sci. 2003;19:1–11.CrossRefPubMed Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, et al. Early microdose drug studies in human volunteers can minimise animal testing, proceedings of a workshop organised by volunteers in research and testing. Eur J Pharm Sci. 2003;19:1–11.CrossRefPubMed
35.
Zurück zum Zitat Japan Pharmaceutical Society. Medical innovation and drugs. Tokyo: Maruzen Co.; 2008. Japan Pharmaceutical Society. Medical innovation and drugs. Tokyo: Maruzen Co.; 2008.
38.
Zurück zum Zitat Keramaris NC, Kanakaris NK, Tzioupis C, Kontakis G, Giannoudis PV. Translational research: from benchside to bedside. Injury. 2008;39:643–50.CrossRefPubMed Keramaris NC, Kanakaris NK, Tzioupis C, Kontakis G, Giannoudis PV. Translational research: from benchside to bedside. Injury. 2008;39:643–50.CrossRefPubMed
39.
Zurück zum Zitat Yamazaki S. Bibliometric analysis of the papers on clinical trials and randomized controlled trials in the Medline database, with reference to the Cochrane Collaboration. Res Bull NACSIS. 1997;9:233–9. Yamazaki S. Bibliometric analysis of the papers on clinical trials and randomized controlled trials in the Medline database, with reference to the Cochrane Collaboration. Res Bull NACSIS. 1997;9:233–9.
41.
Zurück zum Zitat Li T, Ho YS, Li CY. Bibliometric analysis on global Parkinson’s disease research trends during 1991–2006. Neurosci Lett. 2008;441:248–52.CrossRefPubMed Li T, Ho YS, Li CY. Bibliometric analysis on global Parkinson’s disease research trends during 1991–2006. Neurosci Lett. 2008;441:248–52.CrossRefPubMed
42.
Zurück zum Zitat Cambrosio A, Keating P, Mercier S, Lewison G, Mogoutov A. Mapping the emergence and development of translational cancer research. Eur J Cancer. 2006;42:3140–8.CrossRefPubMed Cambrosio A, Keating P, Mercier S, Lewison G, Mogoutov A. Mapping the emergence and development of translational cancer research. Eur J Cancer. 2006;42:3140–8.CrossRefPubMed
44.
Zurück zum Zitat Yamashita Y, Sun Y, Nishizawa M. A case of bibliometric research: analysis of international co-authorship between Japan and foreign countries. J Inf Sci Technol Assoc. 2003;53:9–15. Yamashita Y, Sun Y, Nishizawa M. A case of bibliometric research: analysis of international co-authorship between Japan and foreign countries. J Inf Sci Technol Assoc. 2003;53:9–15.
45.
Zurück zum Zitat Aoki M. The analysis of the documents in the medical information. J Inf Sci Tech Assoc. 2003;53:34–41. Aoki M. The analysis of the documents in the medical information. J Inf Sci Tech Assoc. 2003;53:34–41.
46.
Zurück zum Zitat Smith K, Marinova D. Use of bibliometric modelling for policy making. Math Comput Simul. 2005;69:177–87.CrossRef Smith K, Marinova D. Use of bibliometric modelling for policy making. Math Comput Simul. 2005;69:177–87.CrossRef
47.
Zurück zum Zitat Pober JS, Neuhauser CS, Pober JM. Obstacles facing translational research in academic medical centers. FASEB J. 2001;15:2303–13.CrossRefPubMed Pober JS, Neuhauser CS, Pober JM. Obstacles facing translational research in academic medical centers. FASEB J. 2001;15:2303–13.CrossRefPubMed
48.
Zurück zum Zitat Tho LM, Kathryn G. Translational research:a multidisciplinary approach. Ann Acad Med Singap. 2006;35:441–2.PubMed Tho LM, Kathryn G. Translational research:a multidisciplinary approach. Ann Acad Med Singap. 2006;35:441–2.PubMed
49.
Zurück zum Zitat Wang YXJ. Medical imaging in pharmaceutical clinical trials: what radiologist should know. Clin Radiol. 2005;60:1051–7.CrossRefPubMed Wang YXJ. Medical imaging in pharmaceutical clinical trials: what radiologist should know. Clin Radiol. 2005;60:1051–7.CrossRefPubMed
51.
Zurück zum Zitat Kimura H. Towards promoting research on clinical medicine. SCJ Forum August. 2006;8–11. Kimura H. Towards promoting research on clinical medicine. SCJ Forum August. 2006;8–11.
Metadaten
Titel
Bibliometric study of radiation application on microdose useful for new drug development
verfasst von
Fumio Komoda
Akiko Suzuki
Kazuaki Yanagisawa
Tomio Inoue
Publikationsdatum
01.12.2009
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 10/2009
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-009-0311-z

Weitere Artikel der Ausgabe 10/2009

Annals of Nuclear Medicine 10/2009 Zur Ausgabe